The marine natural product has been an important source of the new pharmaceutical industry in the treatment of various diseases. Liver disease is a leading cause of death in many countries. The measures to control liver disease is still an endeavour to modern medicine. So the present study has been carried out to probe the impregnable, low-cost, active drug from marine gastropod Cypraeaarabica. The whole body extract of Cypraeaarabica was explored for its hepatoprotective effect on paracetamol induced liver damage in Wistar albino rats. Hepatoprotective activities were measured by determining the diagnostic marker enzymes such as SGPT, SGOT, ALP, bilirubin and values were estimated. The hepatic enzymes SGPT (129.62?1.59) (Serum Glutamate Pyruvate Transaminase), SGOT (143.65?1.01) (Serum Glutamate Oxaloacetate Transaminase), ALP (88.93?0.49) (Alkaline Phosphatase) and bilirubin (2.7?0.3) in serum were significantly (P<0.05) increased in paracetamol treated group when compared to control. The F3 fraction of Cypraeaarabica (200 and 400mg/kg) significantly decreased the level of hepatic enzymes and bilirubin. In the liver section of F3 fraction of Cypraeaarabica the normal cellular shape was regained and restored. This result suggests that the Cypraeaarabica extract has a potential therapeutic value in the treatment of liver diseases. - See more at
No comments:
Post a Comment